Literature DB >> 31255207

Evaluation and Management of Neuroendocrine Tumors of the Pancreas.

Aaron T Scott1, James R Howe2.   

Abstract

Pancreatic neuroendocrine tumors are a diverse group of neoplasms with a generally favorable prognosis. Although they exhibit indolent growth, metastases are seen in roughly 60% of patients. Pancreatic neuroendocrine tumors may produce a wide variety of hormones, which are associated with dramatic symptoms, but the majority are nonfunctional. The diagnosis and treatment of these tumors is a multidisciplinary effort, and management guidelines continue to evolve. This review provides a concise summary of the presentation, diagnosis, surgical management, and systemic treatment of pancreatic neuroendocrine tumors.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuroendocrine tumor; PNET; Pancreas; Surgery

Mesh:

Year:  2019        PMID: 31255207      PMCID: PMC6601637          DOI: 10.1016/j.suc.2019.04.014

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  23 in total

Review 1.  [Liver metastases of neuroendocrine tumors].

Authors:  S Nadalin; M Peters; A Königsrainer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-17

Review 2.  Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.

Authors:  Samuel J Galgano; Ajaykumar C Morani; Dheeraj R Gopireddy; Kedar Sharbidre; David D B Bates; Ajit H Goenka; Hina Arif-Tiwari; Malak Itani; Amir Iravani; Sanaz Javadi; Silvana Faria; Chandana Lall; Emily Bergsland; Sadhna Verma; Isaac R Francis; Daniel M Halperin; Deyali Chatterjee; Priya Bhosale; Motoyo Yano
Journal:  Abdom Radiol (NY)       Date:  2022-03-04

Review 3.  Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review.

Authors:  Luca Urso; Alberto Nieri; Ilaria Rambaldi; Angelo Castello; Licia Uccelli; Corrado Cittanti; Stefano Panareo; Irene Gagliardi; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Mirco Bartolomei
Journal:  Endocrine       Date:  2022-08-26       Impact factor: 3.925

4.  A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes.

Authors:  Benjamin D Powers; Luke D Rothermel; Jason B Fleming; Jonathan R Strosberg; Daniel A Anaya
Journal:  J Gastrointest Surg       Date:  2019-11-21       Impact factor: 3.452

5.  Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.

Authors:  Catherine G Tran; Aaron T Scott; Guiying Li; Scott K Sherman; Po Hien Ear; James R Howe
Journal:  Surgery       Date:  2020-06-29       Impact factor: 3.982

Review 6.  Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.

Authors:  Qun Chen; Wu-Jun Wang; Yun-Xuan Jia; Hao Yuan; Peng-Fei Wu; Wan-Li Ge; Ling-Dong Meng; Xu-Min Huang; Peng Shen; Tao-Yue Yang; Yi Miao; Jing-Jing Zhang; Kui-Rong Jiang
Journal:  Cell Biosci       Date:  2021-05-13       Impact factor: 7.133

7.  Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.

Authors:  Courtney A Kaemmer; Shaikamjad Umesalma; Chandra K Maharjan; Devon L Moose; Goutham Narla; Sarah L Mott; Gideon K D Zamba; Patrick Breheny; Benjamin W Darbro; Andrew M Bellizzi; Michael D Henry; Dawn E Quelle
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

8.  RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo.

Authors:  Chandra K Maharjan; Shaikamjad Umesalma; Courtney A Kaemmer; Viviane P Muniz; Casey Bauchle; Sarah L Mott; K D Zamba; Patrick Breheny; Mariah R Leidinger; Benjamin W Darbro; Samuel B Stephens; David K Meyerholz; Dawn E Quelle
Journal:  Biomedicines       Date:  2021-06-02

Review 9.  Surgical Management of Neuroendocrine Tumor Liver Metastases.

Authors:  Catherine G Tran; Scott K Sherman; Chandrikha Chandrasekharan; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2020-10-20       Impact factor: 3.495

10.  Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms.

Authors:  Anna Becker; Camilla Schalin-Jäntti; Outi Itkonen
Journal:  J Endocr Soc       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.